Diabetic nephropathy: Pathogenetic aspects and cardiovascular risk factors

Danish Medical Bulletin

Volumn 49, Issue 1, 2002, Pages 19-42

  Tarnow, Lise ^a  

^a NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CYTOKINE; GROWTH FACTOR; RENIN;

ADULT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FEMALE; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; GLOMERULUS; GLOMERULUS FILTRATION RATE; GLUCOSE METABOLISM; GROWTH RETARDATION; HUMAN; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATHOGENESIS; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SCREENING TEST; SHORT STATURE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; HUMANS; RISK FACTORS;

EID: 0036177165     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (345)

1. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy
2. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study
3. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus
4. The changing natural history of nephropathy in type 1 diabetes
5. Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark
6. Declining incidence of nephropathy in insulin-dependent diabetes mellitus
7. Unchanged incidence of diabetic nephropathy in IDDM patients
8. The natural history of diabetes. 1. Mortality
9. Mortality of type 1 (insulin-dependent) diabetes mellitus in Denmark: A study of relative mortality in 2,930 Danish type 1 diabetic patients diagnosed from 1933 to 1972
10. Prognosis for juvenile diabetics with nephropathy and failing renal function
11. Proteinuria: Value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus
12. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: Incidence and risk-factors
13. Incidence of cardiovascular disease in type 1 diabetic subjects with and without diabetic nephropathy in Finland
14. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy
15. Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion
16. Diabetic nephropathy
17. Dyslipidaemia and other risk factors for coronary heart disease
18. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy
19. Microalbuminuria: An early marker of renal involvement in diabetes
20. Prevalence of microalbuminuria arterial hypertension retinopathy and neuropathy in patients with insulin-dependent diabetes
21. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients
22. The prognosis of insulin-dependent diabetes mellitus. An epidemiological approach
23. Early detection of patients at risk of developing diabetic nephropathy
24. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus
25. Predicting diabetic nephropathy in insulin-dependent patients
26. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria
27. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: A seven-year prospective study
28. Increased expression of basement membrane components in human endothelial cells cultured in high glucose
29. Endothelium-dependent relaxation in aorta from diabetic rats
30. Glucose toxicity for human endothelial cells in culture: Delayed replication disturbed cell cycle and accelerated death
31. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium
32. High glucose inhibits cytosolic calcium signalling in cultured rat mesangial cells
33. Amadori glucose adducts modulate mesangial cell growth and collagen gene expression
34. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: Involvement of the transforming growth factor-beta system
35. Amadori albumin in type 1 diabetic patients - Correlation with markers of endothelial dysfunction association with diabetic nephropathy and localization in retinal capillaries
36. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
37. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats
38. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes
39. Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus
40. Retardation by aminoguanidine of development of albuminuria mesangial expansion and tissue fluorescence in streptozotocin-induced diabetic rat
41. Aldose reductase glomerular metabolism and diabetic nephropathy
42. Prevention of urinary albumin excretion in 6-month streptozotocin-diabetic rats with the aldose reductase inhibitor tolrestat
43. Protein kinase C activation and the development of diabetic complications
44. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-b, extracellular matrix components and prostanoids in the glomeruli of diabetic rats
45. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC b inhibitor
46. Meta-analysis of effects of intensive blood-glucose control on late complications of type 1 diabetes
47. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial
48. Albuminuria reflects widespread vascular damage. The steno hypothesis
49. Microalbuminuria and clinical nephropathy in type 1 (insulin-dependent) diabetes mellitus: Pathophysiological mechanisms and intervention studies
50. Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy
51. Lipids and progressive glomerulosclerosis
52. Dietary induced glomerulosclerosis in the guinea pig
53. Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits -II. Long term studies
54. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats
55. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure
56. Role of hyperlipidemia in progressive renal disease: Focus on diabetic nephropathy
57. Hemodynamic factors in the genesis of diabetic microangiopathy
58. The effect of metabolic control on hemodynamics in short-term insulin-dependent diabetic patients
59. The diabetic arteriole: The impact of diabetic microangiopathy on microcirculatory control
60. Relation of skin capillary pressure in patients with insulin-dependent diabetes mellitus to complications and metabolic control
61. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies
62. Increased kidney size and glomerular filtration rate in early juvenile diabetes
63. Intraglomerular pressure and mesangial stretchning stimulate extracellular matrix formation in the rat
64. The effects of Goldblatt hypertension on development of the glomerular lesions of diabetes mellitus in the rat
65. Dietary protein intake and the progressive nature of renal disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging renal ablation and intrinsic renal disease
66. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
67. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass
68. Diabetic nephropathy and arterial hypertension
69. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V
70. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria
71. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria
72. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria
73. Prevention of diabetic renal disease with special reference to microalbuminuria
74. Effects of lisinopril and nifedipine on the progression of overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure
75. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
76. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus
77. Cigarette smoking as a risk factor for macroproteinuria and proliferative retinopathy in type 1 (insulin-dependent) diabetes
78. The relationship between smoking and microvascular complications in the Eurodiab IDDM Complication Study
79. Cigarette smoking and glomerular filtration rate in insulin-treated diabetics without manifest nephropathy
80. The antidiuretic action of nicotine and of smoking
81. The acute effect of smoking on systemic haemodynamics kidney and endothelial function in insulin-dependent diabetic patients with microalbuminuria
82. Growth factors in glomerulonephritis
83. Hyperglycemia and diabetic kidney disease - The case for transforming growth factor-β as a key mediator
84. Cyclic streching force selectively up-regulates transforming growth factor-β isoforms in cultured rat mesangial cells
85. TGF-β receptor expression and binding in rat mesangial cells: Modulation by glucose and cyclic mechanical strain
86. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy
87. Transforming growth factor β in diabetic nephropathy
88. Elevated D-glucose concentrations modulate TGF-β1 synthesis by human cultured renal proximal tubular cells - The permissive role of platelet-derived growth factor
89. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure
90. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation
91. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells
92. Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissues
93. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes
94. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy
95. VEGF and diabetic microvascular complications
96. Mesangial cells, effect of monocyte products on proliferation and matrix synthesis
97. Shear-stress regulates mesangial interleukin-1b: An in vivo study
98. Effect of isolated GH and IgF-1 deficiency on long-term renal changes and urinary albumin excretion in streptozotocin diabetic dwarf rats
99. Effects of streptozotocin treatment in growth hornone (GH) and GH antagonist transgenic mice
100. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes
101. Octreotide administration in diabetic rats: Effects on renal hypertrophy and urinary albumin excretion
102. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement glomerular hypertrophy and urinary albumin excretion in experimental diabetes in mice
103. Chronic disease in former college students - I. Early precursors of fatal coronary heart disease
104. Stature and the risk of myocardial infarction in women
105. Height and incidence of cardiovascular disease in male physicians
106. Microalbuminuria: Associations with height and sex in nondiabetic subjects
107. Short stature and diabetic nephropathy
108. Low birth weight - A risk factor for development of diabetic nephropathy?
109. Parental height: Childhood environment and subsequent adult height in a national birth cohort
110. Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury
111. Final adult height and its relationship to blood glucose control and microvascular complications in IDDM
112. Short stature and diabetic nephropathy
113. Weight in infancy and death from ischaemic heart disease
114. Fetal and infant growth and impaired glucose tolerance at age 64
115. Initiation of hypertension in utero and its amplication throughout life
116. Growth in utero blood pressure in childhood and adult life and mortality from cardiovascular disease
117. Birth weight and cardiovascular risk factors in an epidemiological study
118. Low birth weight and risk of high blood pressure in adulthood
119. Birth weight and adult hypertension diabetes mellitus and obesity in US men
120. Blood pressure in prospective population based cohort of newborn and infant twins
121. Association between birth weight and adult blood pressure in twins: Historical cohort study
122. Does malnutrition in utero determine diabetes and coronary heart disease in adulthood? Results from the Leningrad siege study, a cross sectional study
123. Effects of maternal protein restriction on the kidney of the newborn young of rats
124. Intrauterine growth retardation leads to a permanent nephron deficit in the rat
125. The effect of intrauterine growth retardation on the development of renal nephrons
126. Low birth weight - Is it associated with few and small glomeruli in normal subjects and NIDDM patients?
127. Glomeruli and blood pressure. Less of one more the other?
128. Familial and perinatal risk factors for micro- and macroalbuminuria in young IDDM patients
129. Birth weight and renal disease in Pima Indians with type 2 diabetes mellitus
130. A new dimension to the Barker hypothesis: Low birth weight and susceptibility to renal disease
131. The Wisconsin epidemiology study of diabetic retinopathy: Proteinuria and retinopathy in a population of diabetic persons diagnosed prior to 30 years of age
132. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes
133. Incidence of end-stage renal disease in type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians
134. Familial clustering of diabetic kidney disease: Evidence of genetic susceptibility to diabetic nephropathy
135. Genetic factors in diabetic nephropathy
136. Is diabetic nephropathy an inherited complication?
137. Familial factors determine the development of diabetic nephropathy in patients with IDDM
138. Clustering of long-term complications in families with diabetes in the diabetes control adn complications trial
139. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus
140. Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM
141. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus
142. Can familial aggregation of disease be explained by familial aggregation of environmental risk factors?
143. Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continous scale
144. Lack of familial predisposition to cardiovascular disease in type 1 (insulin-dependent) diabetic patients with nephropathy
145. The impact of a family history of type II (non-insulin-dependent) diabetes mellitus on the risk of diabetic nephropathy in patients with type I (insulin-dependent) diabetes mellitus
146. Diabetic nephropathy is associated with an increased familial risk of stroke
147. Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy
148. Raised arterial pressure in parents of proteinuric insulin-dependent diabetics
149. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus
150. Sodium-lithium countertransport activity in red cells of patients with insulin-dependent diabetes and nephropathy and their parents
151. Increased blood pressure and erythrocyte sodium-lithium countertransport activity are not inherited in diabetic nephropathy
152. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients
153. + countertransport measurement in essential hypertension, hyperlipidaemia and diabetic nephropathy: A critical review
154. High prevalence of risk factors for cardiovascular disease in parents of IDDM patients with albuminuria
155. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: The EURODIAB IDDM complication study
156. HLA disease associations: Models for insulin dependent diabetes mellitus and the study of complex human genetic disorders
157. Transmission test for linkage disequilibrium: The insulin gene region and insulindependent diabetes mellitus (IDDM)
158. Genetic dissection of complex traits
159. The future of genetic studies of complex human diseases
160. Extreme discordant sibpairs for mapping quantitative trait loci in humans
161. Interpretation of results from genetic studies of multifactorial diseases
162. HLA genotype distribution and genetic models of insulin dependent diabetes mellitus
163. Do genetic factors play a role in the pathogenesis of diabetic microangiopathy?
164. Human leukocyte antigen and insulin gene regions and nephropathy in type 1 diabetes
165. The 5′insulin gene polymorphism and the genetics of vascular complications in type 1 (insulin-dependent) diabetes mellitus
166. Association of the INS VNTR with size at birth
167. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis
168. Gene expression of the reninangiotensin system in human tissues - Quantitative analysis by polymerase chain reaction
169. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy
170. Vascular angiotensin-converting enzyme expression regulates local angiotensin II
171. Serum angiotensin-converting enzyme: Elevations in diabetes mellitus
172. Elevated serum angiotensin I converting enzyme activity in type 1, insulin-dependent diabetic subjects with persistent microalbuminuria
173. Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients
174. Beneficial effect of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy
175. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy
176. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
177. Familial resemblance of plasma angiotensin-converting enzyme level: The Nancy study
178. An insertion/deletion polymorphism in angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels
179. Angiotensin converting enzyme gene polymorphism: Potential silencer motif and impact on progression in IgA nephropathy
180. Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme
181. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation- linkage analysis
182. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications
183. Blood pressure response to withdrawal of converting enzyme inhibition
184. Development of enzyme-linked immounoassays for human angiotensin I converting enzyme suitable for large-scale studies
185. Angiotensin I-converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T-lymphocytes
186. Angiotensin converting enzyme in the human heart: Effects of the deletion/insertion polymorphism
187. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme
188. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects
189. Pressor and humoral responses to angiotensin I infusion in healthy subjects of different angiotensin-converting enzyme genotypes
190. Angiotensin-converting enzyme gene polymorphism is associated with endothelium-dependent vasodilatation in never treated hypertensive patients
191. DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans
192. Angiotensin converting enzyme gene polymorphism and renal artery resistance in patients with insulin dependent diabetes mellitus
193. Angiotensin converting enzyme gene polymorphism and renal hemodynamic function in early diabetes
194. Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes
195. ACE insertion/deletion genotype affects bradykinin metabolism
196. Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough
197. ACE inhibitors, cough, and genetics
198. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
199. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease
200. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction
201. Angiotensin-I converting enzyme (ACE) polymorphism in patients presenting with myocardial infarction or unstable angina
202. Gene polymorphism but not catalytic activity of angiotensin I-converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients
203. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease
204. ACE gene polymorphism: Ischemic heart disease and longevity in 10150 individuals - A case-referent and retrospective cohort study based on the Copenhagen City Heart Study
205. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction
206. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk
207. Blood pressure gene at the angiotensin I-converting enzyme locus - Chronicle of a gene foretold
208. Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in type 1 diabetic patients
209. Ace gene typing
210. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy
211. Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy
212. Ethnic differences in angiotensin converting enzyme gene polymorphism
213. The predictive value of microalbuminuria in IDDM
214. Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration
215. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes
216. Examination of two genetic polymorphisms within the renin-angiotensin system: No evidence for an association with nephropathy in IDDM
217. Association between a polymorphism in the angiotensin-converting enzyme gene and microvascular complications in Japanese patients with NIDDM
218. Meta-analysis of association of insertion/deletion polymorphism of angiotensin 1-converting enzyme gene with diabetic nephropathy and retinopathy
219. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene
220. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: A methodological appraisal and systematic review
221. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients - Findings from the EUCLID randomized controlled trial
222. Contribution of angiotensin I converting enzyme I/D polymorphism to the development and progression of nephropathy in type 1 diabetes
223. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow up study
224. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus
225. Relation between blood pressure and renin, renin substrate, angiotensin II, aldosterone and urinary sodium and potassium in 574 ambulatory subjects
226. Molecular basis of human hypertension: Role of angiotensinogen
227. Linkage of the angiotensinogen gene to essential hypertension
228. Angiotensinogen as a risk factor for essential hypertension in Japan
229. Angiotensinogen gene in human hypertension
230. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro
231. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity
232. M235T angiotensinogen gene polymorphism and cardiovascular renal risk
233. Diabetic nephropathy is associated with AGT polymorphism 235 - Results of a family-based study
234. Angiotensinogen gene M235T polymorphism is not associated with diabetic nephropathy
235. Angiotensinogen polymorphism M235T, hypertension, and nephropathy in insulin-dependent diabetes
236. Genetic variants of the renin-angiotensin system, diabetic nephropathy and hypertension
237. A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM
238. Angiotensin II type 1 receptor gene polymorphism in human essential hypertension
239. Angiotensin II type 1 receptor gene polymorphism predicts response to Iosartan and angiotensin II
240. A polymorphism in the gene for the angiotensin II type 1 receptor is not associated with hypertension
241. Influence of angiotensin II type 1 receptor polymorphsim on aortic stiffness in never-treated hypertensive patients
242. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy
243. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction
244. Lack of association of angiotensin II type 1 receptor gene polymorphism with diabetic nephropathy in insulin-dependent diabetes mellitus
245. Synergistic effet of angiotensin II type 1 receptor genotype and poor glycaemic control on risk of nephropathy in IDDM
246. Risk of developing diabetic nephropathy is not associated with synergism between the angiotensin II (type 1) receptor C1166 allele and poor glycaemic control
247. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q - Results of novel discordant sib-pair analysis
248. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes
249. Diabetes and hypertensive vascular disease: Mechanisms and treatment
250. Renin in diabetes mellitus
251. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications
252. High plasma prorenin in diabetes mellitus and its correlation with some complications
253. Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents
254. Serum total renin is increased before microalbuminuria in diabetes
255. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus
256. Application of denaturing gradient gel electrophoresis to detect DNA polymorphisms in the renin gene in IDDM patients with and without diabetic nephropathy
257. Similar frequencies of renin gene restriction fragment length polymorphisms in hypertensive and normotensive subjects
258. Genetic variation of the heparan sulfate proteoglycan gene (Perlecan gene) - Association with urinary albumin excretion in IDDM patients
259. Genetic variation of a collagen IV alfa 1-chain gene polymorphism in Danish insulin-dependent diabetes mellitus (IDDM) patients: Lack of association to nephropathy and proliferative retinopathy
260. Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus
261. Polymorphisms in the interleukin-1 gene cluster do not contribute to the genetic susceptibility of diabetic nephropathy in Caucasian patients with IDDM
262. An interleukin 1B allele, which correlates with a high secretor phenotype, is associated with diabetic nephropathy
263. TGF-beta1 gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy
264. Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropahty in type 1 diabetes
265. The 5′-end polymorphsim of the aldose reductase gene is not associated with diabetic nephropathy in Caucasian type 1 diabetic patients
266. Blood pressure, stroke and coronary heart disease, part I: Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias
267. Blood pressure, stroke, and coronary heart disease, part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
268. The effect of treatment on mortality in "mild" hypertension: Results of the hypertension detection and follow-up program
269. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
270. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
271. Prevalence of hypertension in type 1 (insulin-dependent) diabetes mellitus
272. Diabetes mellitus and hypertension
273. Recognition of hypertension and abnormal blood pressure burden with ambulatory blood pressure recordings in type 1 diabetes mellitus
274. Circadian variation of blood pressure in patients with diabetic nephropathy
275. Treatment of hypertension in diabetes
276. The fifth report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC-V)
277. Prevalence and management of hypertension in type 1 diabetes mellitus in Europe: The EURODIAB IDDM complications study
278. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
279. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension
280. The heart in hypertension
281. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension
282. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
283. Cardiac disease in diabetic end-stage renal disease
284. Echocardiographic-determined left ventricular wall characteristics in insulin-dependent diabetic patients
285. Cardiac hyperfunction in insulin-dependent diabetic patients developing microvascular complications
286. Intraventricular septal hypertrophy in type 1 diabetic patients with microalbuminuria or early proteinuria
287. Prevalence of left ventricular hypertrophy in type 1 diabetic patients with diabetic nephropathy
288. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
289. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method
290. Clinical impact of various geometric models for calculation of echocardiographic left ventricular mass
291. Echocardiographic criteria for left ventricular hypertrophy: The Framingham Heart Study
292. Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy
293. Increased left ventricular mass in normotensive type 1 diabetic patients with diabetic nephropathy
294. Echocardiographically detected left ventricular hypertrophy: Prevalence and risk factors
295. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension
296. Dietary salt intake. A determinant of cardiac involvement in essential hypertension
297. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome
298. Association between left ventricular hypertrophy and erythrocyte sodium-lithium exchange in normotensive subjects with and without NIDDM
299. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes
300. Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system
301. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy
302. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death
303. Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass
304. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training
305. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)
306. Regression of left ventricular hypertrophy with 1 year of antihypertensive treatment in type 1 diabetic patients with early nephropathy
307. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment
308. Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension
309. Prognostic significance of serial changes in left ventricular mass in essential hypertension
310. Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy
311. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys
312. The electrocardiogram in population studies: A classification system
313. Aortic atherosclerosis in diabetes mellitus is associated with an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene
314. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus
315. UK prospective diabetes study (UKPDS) 14: Association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM
316. Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM
317. Lipoprotein Lp (a) excess and coronary heart disaese
318. Serum Lp (a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria
319. Apolipoprotein (a) in insulin-dependent diabetic patients with and without diabetic nephropathy. Scand
320. Levels of Lipoprotein (a), Apolipoprotein B, and Lipoprotein cholesterol distribution in IDDM Results from follow-up in the Diabetes Control and Complications Trial
321. Lipoprotein (a) concentration shows little relationship to IDDM complications in the Pittsburgh epidemiology of diabetes complications study cohort
322. Lipoprotein (a) and vascular disease in diabetic patients
323. Association of elevated lipoprotein (a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein (a) phenotypes
324. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor
325. The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients wit coronary heart disease
326. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia
327. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
328. Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy
329. Glomerular hyperfiltration as a risk factor for diabetic nephropathy: Five year report of a prospective study
330. Increased glomerular filtration rate as a predictor of diabetic nephropathy - An 8-year prospective study
331. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: A cohort study
332. Polymorphism of complement C4 and susceptibility to IDDM and microvascular complications
333. A CCTTT-repeat polymorphsim in the human NOS2-promoter confers low risk of diabetic nephropathy in type 1 diabetic patients
334. Pronatriodilatin gene polymorphisms, microvascular permeability, and diabetic nephropathy in type 1 diabetes mellitus
335. The C825T polymorphism in the human G-protein beta3 subunit is not associated with diabetic nephropathy in type 1 diabetes mellitus
336. Association of apolipoprotein E2 allele with diabetic nephropathy in Caucasian subjects with IDDM
337. Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic nephropathy
338. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients
339. The N-acetyltransferase (NAT) gene: An early risk marker for diabetic nephropathy in Japanese type 2 diabetic patients?
340. The Trp64Arg amino acid polymorphism of the beta-3-adrenergic receptor gene does not contribute to the genetic susceptibility of diabetic microvascular complications in Caucasian type 1 diabetic patients
341. Glucose transporter (GLUTI) allele (Xbal-) associated with nephropathy in non-insulin-dependent diabetes mellitus